Corcept Therapeutics Incorporated (CORT)
| Market Cap | 7.96B -1.2% |
| Revenue (ttm) | 963.65M +30.0% |
| Net Income | 159.36M +52.9% |
| EPS | 1.33 +52.2% |
| Shares Out | 109.44M |
| PE Ratio | 54.74 |
| Forward PE | 16.64 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,406,677 |
| Open | 73.60 |
| Previous Close | 71.63 |
| Day's Range | 72.17 - 74.86 |
| 52-Week Range | 28.66 - 126.38 |
| Beta | 0.56 |
| Analysts | Buy |
| Price Target | 142.60 (+95.96%) |
| Earnings Date | Nov 3, 2026 |
About CORT
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortis... [Read more]
Financial Performance
In 2025, Corcept Therapeutics's revenue was $761.41 million, an increase of 12.79% compared to the previous year's $675.04 million. Earnings were $98.17 million, a decrease of -29.74%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for CORT stock is "Buy." The 12-month stock price target is $142.6, which is an increase of 95.96% from the latest price.
News
Corcept Therapeutics price target raised to $173 from $165 at Piper Sandler
Piper Sandler analyst David Amsellem raised the firm’s price target on Corcept Therapeutics (CORT) to $173 from $165 and keeps an Overweight rating on the shares. The firm notes Corcept…
Corcept Therapeutics Earnings Call Transcript: Q3 2026
Q3 revenue rose 64% YoY to $340.5M, with $91.4M from Lifyorli; FY2026 guidance remained $1.1B-$1.2B. Management highlighted broader hypercortisolism screening, oncology growth, and multiple clinical catalysts ahead.
Corcept Therapeutics Earnings release: Q3 2026
Corcept Therapeutics released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Corcept Therapeutics Quarterly report: Q3 2026
Corcept Therapeutics has published its Q3 2026 quarterly earnings report on November 3, 2026.
Corcept Therapeutics reports Q3 EPS $1.01, consensus 84c
Reports Q revenue $340.5M, consensus $336.4M. “Awareness of the importance of diagnosing and treating patients with Cushing’s syndrome is steadily increasing and is driving the growth of our endocrino...
Corcept Therapeutics affirms FY26 revenue view $1.1B-$1.2B, consensus $1.15B
16:15 EST Corcept Therapeutics (CORT) affirms FY26 revenue view $1.1B-$1.2B, consensus $1.15B
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics Slides: Investor presentation
Corcept Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 3, 2026.
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 202...
Corcept announces results from Part A of Phase 2 BELLA trial of Lifyorli
Corcept Therapeutics (CORT) announced positive results from Part A of the company’s Phase 2 BELLA trial, which evaluated Lifyorli in combination with nab-paclitaxel and bevacizumab in 95 patients with...
Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Why Healthcare Stocks Are Hot When the AI Trade Runs Cold
Healthcare—particularly equipment and services and pharmaceuticals—offers investors diversification from AI, according to one report.
Corcept Therapeutics president of endocrinology Sean Maduck to retire
Corcept Therapeutics (CORT) announced the retirement of Sean Maduck, President of the company’s Endocrinology division. Justin Gunn will succeed Mr. Maduck and will fully assume his new responsibiliti...
Corcept Announces Planned Leadership Transition
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept announces positive CHMP opinion for Lifyorli
Corcept Therapeutics (CORT) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended that the European Commission should approve relacorilant, comb...
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Grows to Mid-Cap on Institutional Support
Institutions keep buying Corcept Therapeutics Incorporated (CORT) shares in big volumes, sending them up 1,016% since 2017 and on the cusp of joining the S&P MidCap 400 index.
Corcept Therapeutics assumed with a Buy at Truist
Truist assumed coverage of Corcept Therapeutics (CORT) with a Buy rating with a price target of $164, up from $50. The form is positive on the company’s opportunity in Cushing’s,…
Raised Guidance Lifts Corcept to 52-Week High
CORT discovers, develops, and sells medications to treat severe metabolic, oncologic, and psychiatric disorders, focusing on the hormone cortisol (over 1,000 proprietary modulators) as well as Cushing...
Corcept Therapeutics price target raised to $161 from $150 at Canaccord
Canaccord analyst Edward Nash raised the firm’s price target on Corcept Therapeutics (CORT) to $161 from $150 and keeps a Buy rating on the shares. The firm said Corcept reported…
Corcept Therapeutics price target raised to $165 from $88 at Piper Sandler
Piper Sandler raised the firm’s price target on Corcept Therapeutics (CORT) to $165 from $88 and keeps an Overweight rating on the shares. The firm notes Corcept reported Q2 diluted…
Corcept Therapeutics price target raised to $165 from $95 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Corcept Therapeutics (CORT) to $165 from $95 and keeps a Buy rating on the shares. The firm says Lifyorli’s “rapid ramp” and…
Corcept Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 32% year-over-year to $256.1 million, driven by strong launches in both endocrinology and oncology. LIFYORLI saw rapid uptake with over 1,300 patients treated, and guidance was raised to $1.1–$1.2 billion for 2026.
Corcept Therapeutics Earnings release: Q2 2026
Corcept Therapeutics released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.